drugset / Trial / NCT05499351

A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine

NCT05499351

Phase 4 Completed 3000 enrolled Sinovac Biotech Co., Ltd
RandomizedParallel-groupOpen-labelPrevention

Summary

This study is a single center , randomized ,controlled and open-label phase Ⅳclinical trial of the booster immunization with the third dose of inactivated COVID-19 vaccine(CoronaVac)manufactured by Sinovac Research \& Development Co.,Ltd. The purpose of this study is to evaluate the immunogenicity and safety of the third dose of COVID-19 vaccine,inactivated (Vero Cell) co-administration with influenza vaccine and pneumococcal polysaccharide vaccine in healthy population aged 18 years and older.

Timeline

Start
2021-10-15
Primary completion
2021-12-05
Completion
2022-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CoronaVac Vaccine 600 unknown Other
Subject Pneumovax 23 Vaccine 0.5 ml Other
Subject Quadrivalent influenza vaccine Vaccine 15 ug Other

Indications